Pemetrexed Injection IP 500 mg

Product Description

Pemetrexed injection IP 500 mg is an antifolate drug used to treat certain types of lung cancer and mesothelioma. Pemetrexed injection IP 500 mg is approved by the U.S. Food and Drug Administration (FDA) for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Pemetrexed injection IP 500 mg may be used alone or in combination with other chemotherapy drugs, depending on the type and stage of cancer being treated. Common side effects of pemetrexed injection IP 500 mg may include fatigue, nausea, vomiting, mouth sores, loss of appetite, hair loss, and diarrhea.

Powerful Cancer Treatment

Pemetrexed Injection IP 500 mg effectively targets cancer cells in conditions like Non-Small Cell Lung Cancer and Malignant Pleural Mesothelioma. Its cytotoxic action disrupts cancer cell growth, providing significant therapeutic benefits as part of chemotherapy regimens. The single-use vial ensures precise dosing and maintains product integrity.


Strict Safety and Quality Measures

This medication is manufactured to GMP standards, guaranteeing consistent quality and safety. Each vial, containing 500 mg of lyophilized powder, undergoes rigorous quality checks. Storage below 25C and protection from light preserve its efficacy throughout its 24-month shelf life.


Professional Administration and Monitoring

Pemetrexed Injection must be prepared and administered exclusively in medical settings by trained professionals. The infusion process, monitored for potential side effects like myelosuppression, maximizes safety for patients undergoing chemotherapy therapies.